Related Experiment Video
Updated: Jun 3, 2025

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
Published on: February 3, 2022
Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth
Ohuod Hawsawi1, Weinan Xue1, Tingting Du2
1Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Abstract:
Mitochondrial uncouplers dissipate proton gradients and deplete ATP production from oxidative phosphorylation (OXPHOS). While the growth of prostate cancer depends on OXPHOS-generated ATP, the oncogenic pathway mediated by the transcription factor E2F1 is crucial for the progression of this deadly disease. Here, we report that mitochondrial uncouplers, including tizoxanide (TIZ), the active metabolite of the Food and Drug Administration (FDA)-approved anthelmintic nitazoxanide (NTZ), inhibit E2F1-mediated expression of genes involved in cell cycle progression, DNA synthesis, and lipid synthesis. Consequently, NTZ/TIZ induces S-phase kinase-associated protein 2 (SKP2)-mediated G1 arrest while impeding DNA synthesis, lipogenesis, and the growth of prostate cancer cells. The anti-cancer activity of TIZ correlates with its OXPHOS-uncoupling activity. NTZ/TIZ appears to inhibit ATP production, thereby activating the AMP-activated kinase (AMPK)-p38 pathway, leading to cyclin D1 degradation, Rb dephosphorylation, and subsequent E2F1 inhibition. Our results thus connect OXPHOS uncoupling to the inhibition of an essential oncogenic pathway, supporting repositioning NTZ and other mitochondrial uncouplers for prostate cancer therapy.
Insights
Mitochondrial uncouplers like nitazoxanide (NTZ) inhibit prostate cancer growth by blocking the E2F1 pathway. This FDA-approved drug disrupts energy production, offering a new therapeutic strategy for prostate cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer growth relies on ATP from oxidative phosphorylation (OXPHOS).
- The E2F1 pathway is critical for prostate cancer progression.
- Mitochondrial uncouplers disrupt cellular energy production.
Purpose of the Study:
- To investigate the effect of mitochondrial uncouplers on E2F1-mediated pathways in prostate cancer.
- To determine if nitazoxanide (NTZ) and its metabolite tizoxanide (TIZ) can inhibit prostate cancer cell growth.
- To explore the underlying molecular mechanisms of NTZ/TIZ anti-cancer activity.
Main Methods:
- Treatment of prostate cancer cells with NTZ/TIZ.
- Analysis of gene expression related to cell cycle, DNA synthesis, and lipid synthesis.
- Assessment of cell cycle arrest, DNA synthesis, and lipogenesis.
- Investigation of the AMP-activated kinase (AMPK)-p38 signaling pathway.
Main Results:
- NTZ/TIZ inhibited E2F1-mediated gene expression crucial for cell cycle and biosynthesis.
- NTZ/TIZ induced G1 cell cycle arrest and impeded DNA synthesis and lipogenesis.
- The anti-cancer effects of TIZ correlated with its OXPHOS-uncoupling activity.
- NTZ/TIZ activated the AMPK-p38 pathway, leading to E2F1 inhibition.
Conclusions:
- Mitochondrial uncoupling inhibits a key oncogenic pathway in prostate cancer.
- NTZ/TIZ demonstrates anti-cancer activity by disrupting OXPHOS and inhibiting E2F1.
- Repositioning NTZ and other mitochondrial uncouplers for prostate cancer therapy is supported.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitogens and the Cell Cycle
Abnormal Proliferation
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

